BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37666354)

  • 1. Effect of transplanted cells with CD184 and CD26 expressions and reconstitution of CD3+ lymphocyte population on long-term survival after autologous hematopoietic stem cell transplantation for multiple myeloma.
    Kopinska A; Krawczyk-Kulis M; Wieczorkiewicz-Kabut A; Koclega A; Jagoda K; Dziaczkowska-Suszek J; Helbig G
    Exp Hematol; 2023 Nov; 127():52-58.e1. PubMed ID: 37666354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of the number of transplanted cells with dipeptidyl peptidase-4 expression on the haematopoietic recovery and lymphocyte reconstitution in patients with multiple myeloma after autologous haematopoietic stem-cell transplantation.
    Kopinska A; Krawczyk-Kulis M; Dziaczkowska-Suszek J; Bieszczad K; Jagoda K; Kyrcz-Krzemien S
    Hematol Oncol; 2017 Jun; 35(2):225-231. PubMed ID: 28620928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apheresis-related enrichment of CD26++ T lymphocytes: phenotypic characterization and correlation with unfavorable outcome in autologous hematopoietic progenitor cell transplantation.
    Hildebrandt M; Dijkstra D; Gollasch H; Daemen K; Stevanovic-Meyer M; Ludwig WD
    Transfusion; 2012 Apr; 52(4):765-76. PubMed ID: 21950525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.
    Turunen A; Silvennoinen R; Partanen A; Valtola J; Siitonen T; Putkonen M; Sankelo M; Pyörälä M; Kuittinen T; Penttilä K; Sikiö A; Savolainen ER; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Transfusion; 2021 Jun; 61(6):1830-1844. PubMed ID: 33955591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
    Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: potential predictor of early engraftment.
    Prabhash K; Khattry N; Bakshi A; Karandikar R; Joshi A; Kannan S; Sastry PSRK; Parikh P; Kode JA
    Ann Oncol; 2010 Mar; 21(3):582-588. PubMed ID: 19759183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
    Wei M; Xie C; Huang J; Liu Q; Lai Y
    Hematology; 2023 Dec; 28(1):2269509. PubMed ID: 37850613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
    Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
    Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34
    Salzmann-Manrique E; Bremm M; Huenecke S; Stech M; Orth A; Eyrich M; Schulz A; Esser R; Klingebiel T; Bader P; Herrmann E; Koehl U
    Front Immunol; 2018; 9():1841. PubMed ID: 30154788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
    Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation.
    Richter S; Böttcher M; Stoll A; Zeremski V; Völkl S; Mackensen A; Ekici AB; Jacobs B; Mougiakakos D
    Transplant Cell Ther; 2024 Mar; ():. PubMed ID: 38460727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study.
    Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Putkonen M; Partanen A; Pyörälä M; Savolainen ER; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
    Leuk Lymphoma; 2019 Feb; 60(2):453-461. PubMed ID: 30160591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation.
    Heck C; Steiner S; Kaebisch EM; Frentsch M; Wittenbecher F; Scheibenbogen C; Hanitsch LG; Nogai A; le Coutre P; Bullinger L; Blau IW; Na IK
    Front Immunol; 2021; 12():736137. PubMed ID: 34659226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome after allogeneic stem cell transplantation in multiple myeloma.
    Luoma S; Silvennoinen R; Rauhala A; Niittyvuopio R; Martelin E; Lindström V; Heiskanen J; Volin L; Ruutu T; Nihtinen A
    Ann Hematol; 2021 Jun; 100(6):1553-1567. PubMed ID: 33866396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
    Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
    Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
    Olin RL; Vogl DT; Porter DL; Luger SM; Schuster SJ; Tsai DE; Siegel DL; Cook RJ; Mangan PA; Cunningham K; Stadtmauer EA
    Bone Marrow Transplant; 2009 Mar; 43(5):417-22. PubMed ID: 18850013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
    Muta T; Miyamoto T; Fujisaki T; Ohno Y; Kamimura T; Kato K; Takenaka K; Iwasaki H; Eto T; Takamatsu Y; Teshima T; Akashi K;
    Intern Med; 2013; 52(1):63-70. PubMed ID: 23291675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.